Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 8:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CBD 20 mg Clear all
Completed Phase 3 Interventional Results available

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

NCT00357994
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa carbidopa intestinal gel (LCIG), Placebo gel, Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 7, 2026, 8:02 PM EDT
Terminated Phase 4 Interventional Results available

Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain

NCT03891264
View directory record Official record
Conditions
Back Pain, Low
Interventions
Cannabidiol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Sep 7, 2026, 8:02 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Cannabidiol in Sanfilippo Syndrome

NCT06333041
View directory record Official record
Conditions
Sanfilippo Syndrome, Mucopolysaccharidosis III
Interventions
Epidiolex, Placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
4 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 7, 2026, 8:02 PM EDT
Not yet recruiting Phase 3 Interventional

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

NCT07148206
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol, Placebo Epidiolex
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 7, 2026, 8:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

NCT02224690
View directory record Official record
Conditions
Epilepsy, Lennox-Gastaut Syndrome
Interventions
GWP42003-P 20 mg/kg/day Dose, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 55 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
17
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 7, 2026, 8:02 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome

NCT03458416
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 7, 2026, 8:02 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy

NCT06859710
View directory record Official record
Conditions
Abuse, Drug, Pain
Interventions
Placebo, THC, CBD 20 mg, CBD 40 mg, CBD 80 mg
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 7, 2026, 8:02 PM EDT
Completed Phase 2 Interventional

12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa

NCT00456794
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Istradefylline (KW-6002)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 7, 2026, 8:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders

NCT02324673
View directory record Official record
Conditions
Seizures
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
1 Year to 17 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
San Francisco, California • Miami, Florida • Pensacola, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 7, 2026, 8:02 PM EDT
Completed Phase 2 Interventional

The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy

NCT04088929
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
CBD
Drug
Lead sponsor
Pure Green
Industry
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Sterling Heights, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 7, 2026, 8:02 PM EDT
Completed Phase 3 Interventional Results available

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

NCT00360568
View directory record Official record
Conditions
Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
Interventions
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 7, 2026, 8:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

NCT02224560
View directory record Official record
Conditions
Epilepsy, Lennox Gastaut Syndrome
Interventions
GWP42003-P, Placebo control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 55 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 7, 2026, 8:02 PM EDT
Active, not recruiting Phase 2 Interventional

Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism

NCT04517799
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Epidiolex, placebo oral solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
7 Years to 14 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 7, 2026, 8:02 PM EDT
Not yet recruiting Phase 2 Interventional

Epidiolex Trial for Presymptomatic Treatment of Sturge-Weber Syndrome

NCT07778810
View directory record Official record
Conditions
Sturge - Weber Syndrome (SWS)
Interventions
Epidiolex 100 mg/mL Oral Solution
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Month to 18 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 7, 2026, 8:02 PM EDT
Completed Phase 1 Interventional

Treatment of Orthostatic Hypotension in Autonomic Failure

NCT00223691
View directory record Official record
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 7, 2026, 8:02 PM EDT
Terminated Phase 2 Interventional Results available

Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms

NCT02551731
View directory record Official record
Conditions
Spasms, Infantile
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
6 Months to 36 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 7, 2026, 8:02 PM EDT
Completed Phase 3 Interventional Results available

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

NCT00660673
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy® 1400 ambulatory infusion pump, Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)
Drug · Device
Lead sponsor
AbbVie
Industry
Eligibility
30 Years to 99 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
31
States / cities
Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 7, 2026, 8:02 PM EDT
Completed Phase 2 Interventional Results available

Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome

NCT04447846
View directory record Official record
Conditions
Sturge-Weber Syndrome
Interventions
Cannabidiol
Drug
Lead sponsor
Anne Comi, MD
Other
Eligibility
3 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Sep 7, 2026, 8:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cannabidiol and Focus Study (CBD-Focus)

NCT05189275
View directory record Official record
Conditions
Healthy
Interventions
Daily Beverage Intervention
Dietary Supplement
Lead sponsor
University of Northern Colorado
Other
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Greeley, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Sep 7, 2026, 8:02 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome

NCT05098509
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
RAD011, Placebo
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Sep 7, 2026, 8:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Effects of CBD Products on Anxiety Among U.S. Women

NCT05108220
View directory record Official record
Conditions
Anxiety, Generalized Anxiety Disorder
Interventions
Cannabidiol (CBD)- containing consumer products
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
24 Years to 44 Years · Female only
Enrollment
1,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 7, 2026, 8:02 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of CBN With and Without CBD on Sleep Quality

NCT05839964
View directory record Official record
Conditions
Healthy Adults
Interventions
CBN and CBD
Dietary Supplement
Lead sponsor
Canopy Growth Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 7, 2026, 8:02 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures

NCT05288283
View directory record Official record
Conditions
Seizures Associated With EMAS
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 7, 2026, 8:02 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluation of Oral THC and CBD in Men and Women

NCT05067387
View directory record Official record
Conditions
Drug Abuse, Intoxication by Drug, Impairment
Interventions
Placebo, THC, CBD, THC + CBD
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 7, 2026, 8:02 PM EDT